Skip to main content

Column Group L P's Form 4 filing

NGM Biopharmaceuticals Inc (NGM) · filed May 13, 2022

Accession no.
0000899243-22-018030
Filed
May 13, 2022, 5:30 PM ET
Trade date
May 11-12, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 8 non-derivative transactions. Open-market purchases total $1.90M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Column Group L PCIK 0001347769Director, 10% Owner
Column Group II, LPCIK 000160042010% Owner
Svennilson PeterCIK 000160607410% Owner
Kutzkey TimCIK 000161418610% Owner
Column Group II GP, LPCIK 000164533310% Owner
Column Group Management LPCIK 000164534010% Owner
Ponoi Capital, LPCIK 000170723010% Owner
Ponoi Management, LLCCIK 000172070210% Owner
Ponoi Capital II, LPCIK 000173260110% Owner
Ponoi II Management, LLCCIK 000174648810% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 11, 2022Common StockPPurchaseAcquired+77,866$11.23F1+$874,108.141,010,189Indirect
May 11, 2022Common StockPPurchaseAcquired+2,657$11.23F1+$29,826.9534,475Indirect
May 11, 2022Common StockPPurchaseAcquired+2,564$11.85F4+$30,376.481,012,753Indirect
May 11, 2022Common StockPPurchaseAcquired+88$11.85F4+$1,042.5634,563Indirect
May 12, 2022Common StockPPurchaseAcquired+79,945$11.62F5+$929,048.841,092,698Indirect
May 12, 2022Common StockPPurchaseAcquired+2,728$11.62F5+$31,702.3637,291Indirect
May 12, 2022Common StockPPurchaseAcquired+485$11.81F6+$5,725.761,093,183Indirect
May 12, 2022Common StockPPurchaseAcquired+17$11.81F6+$200.737,308Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.745 to $11.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Referenced by the price of 2 transactions in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.76 to $11.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4.

Referenced by the price of 2 transactions in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.73 to $11.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (5) to this Form 4.

Referenced by the price of 2 transactions in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.74 to $11.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (6) to this Form 4.

Referenced by the price of 2 transactions in Table I.

Remarks

Due to SEC restrictions on the number of reporting owners, this is Form 1 of 2.

Read the full filing on SEC EDGAR (opens in a new tab)